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Ectonucleotide pyrophosphatase/phosphodiesterase 1, which downregulates insulin signaling by 
inhibiting insulin-receptor tyrosine kinase activity, is encoded by the ENPP1 gene. Common 
variants in ENPP1 have been associated with body mass index (BMI), diabetes and glycemia 
related traits in populations of European Ancestry, but data in African ancestry populations are 
sparse.  Our objective was to evaluate common ENPP1 variants for association with diabetes and 
glycemia related traits in a high risk Afro-Caribbean population. Thirty-four single nucleotide 
polymorphisms (SNPs) based on pair-wise tagging (r2 ≥ 0.80; MAF ≥ 0.05) were successfully 
genotyped in 380 cases and 1,455 controls without diabetes. Associations with BMI, fasting 
glucose, fasting insulin and HOMA-IR were also analyzed in non-diabetic controls. The most 
interesting association was observed between rs1044498 K121 allele and lower BMI (age-
adjusted P = 0.018). Nominal associations were observed with ENPP1 SNPs and fasting glucose 
(age-and BMI-adjusted P=0.001 to 0.020). Also, six SNPs showed nominal evidence for 
association (P ≤ 0.05) with diabetes in one or more genotypic model. The most significant 
associations were observed with SNPs in intron 11 (rs17060836; OR=1.32 [1.04-1.67]; dominant 
P = 0.019), two SNPs in intron 1 (rs703184, rs7749493; OR= 0.78 to 1.39) and three SNPs in the  
3’untranslated region (rs7754561, rs7769993 and rs9373000; OR = 0.69-1.38). In this population  
of Afro-Caribbean men, the ENPP1-rs1044498 the K121 allele and intronic variants may  
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modulate BMI and glucose. Also, variants in the 3’UTR confer an increased risk of developing 
diabetes confirming and extending reports in European and African Americans. After accounting  
for multiple testing, we conclude that ENPP1 is not a major contributor to diabetes related traits;  
nevertheless, our results reveal that variants in the ENPP1 gene may modulate BMI and maintain 
glucose homeostasis in this population of Afro-Caribbean men. These studies are of public health 
relevance or importance because they contribute epidemiologic information to the genetic 
etiology of type 2 diabetes in men of African ancestry. 
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1.0 INTRODUCTION 
1.1 DIABETES 
Diabetes is a disease that is characterized by high blood glucose levels due to the body’s inability 
to produce insulin, and/or the body’s inability to respond properly to insulin.  Clinically, diabetes 
is diagnosed if an individual has a fasting blood glucose level of 126 mg/dl or higher using the 
Fasting Plasma Glucose Test (FPGT), or a two-hour blood glucose level greater than or equal to 
200 mg/dl using the Oral Glucose Tolerance Test (OGTT) 1.  Diabetes is a growing epidemic in 
the United States and worldwide.  It is currently estimated that 20.8 million people, or 7% of the 
total US population, have diabetes, of which 6.2 million (nearly one-third) are undiagnosed 
(2007, Kaiser Family Foundation).  In 2005 there were 1.5 million new cases of diabetes in 
Americans aged 20 years and older 2.  Diabetes is the sixth leading cause of death in the United 
States and has a major impact on both the economy and health 3.  In 2002, diabetes costs in the 
United States totaled $132 billion in both direct and indirect costs 4.  Diabetes and complication 
due to diabetes can greatly affect quality of life.  Diabetes can reduce one’s life expectancy 5-10 
years, increases the risk for stroke 2-4 times, and is the leading cause of kidney failure, non-
traumatic lower-limb amputations, and blindness 2.  
 
There are multiple types of diabetes including type 1, type 2, and gestational diabetes.  The most 
prevalent form of diabetes, type 2 diabetes mellitus (T2D), accounts for 90-95% of all cases of 
diabetes.  T2D is a complex disease with both genetic and environmental influences.  Risk 
factors for developing T2D include older age, obesity, physical inactivity, and a family history of  
diabetes 4.  Additionally, certain ethnicities such as African Americans, Hispanic/Latino 
Americans, and American Indians, have a higher risk for developing T2D.  In the United States, 
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3.2 million African Americans aged 20 years and older, or 13.3% of the nation’s African 
American population, have diabetes (2007, Kaiser Family Foundation).  On average, an African 
American is nearly two times more likely to develop diabetes as compared to a European 
American of similar age 5.  African Americans are also at increased risk for complications 
associated with diabetes, including amputation rates (1.2-1.5 times higher) 6, and kidney disease, 
including end-stage renal disease (2.6-5.6 times greater) 7, as compared to European Americans.  
Mortality rates, due to diabetes, are also higher for African American as compared to European 
Americans.  In 2003, diabetes accounted for 49.2 deaths per 100,000 population in African 
Americans as compared to 23.0 deaths per 100,000 population in Caucasians 8. 
 
1.2 GENETICS OF TYPE 2 DIABETES 
Genetic epidemiological studies support evidence that several variables contribute to T2D risk, 
including multiple genetic loci with small effect, environmental factors, and genetic 
heterogeneity 9.  Evidence of a genetic contribution to T2D susceptibility has been established 
through twin 10, familial aggregation 11, and segregation studies 12.  Barnett et al, 1981 showed 
that 48 of 53 middle aged or elderly monozygotic twins were concordant for T2D (>90% 
concordant rate).  Of the five discordant twin pairs, all of the unaffected twins were beginning to 
show metabolic abnormalities (i.e. reduced insulin response to glucose) at the time of the report 
13.  Goodman and Chung, 1975 calculated that the heritability (h2) for diabetes in individuals 
aged 40 years and older (assuming a multifactorial mode of inheritance) was 0.66 12.  This  
estimate was supported by h2 values of 0.70 for T2D by Rich (1990), who also reported risk 
ratios of 12.3, 3.5, and 1.9 for monozygotic twins, first degree relatives, and second degree  
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relatives of probands with T2D; respectively 9.  Similarly, familial aggregation studies reveal that 
relatives of African American probands with T2D had a 2.95 fold increased prevalence of 
diabetes (95% CI = 1.55-6.62) as compared to relatives of unaffected individuals 11.  
 
1.3 IDENTIFYING GENES FOR COMPLEX DISEASES 
Until the recent use of Genome Wide Association Studies (GWAS), the two commonly used 
methods for identifying genes for complex diseases were the candidate gene approach and the 
positional cloning approach.  The candidate gene approach evaluates variants in genes of known 
function and relevance to a particular phenotype.  For example, logical candidate genes for T2D 
susceptibility have included genes related to insulin (e.g. the genes encoding the insulin protein 
or the insulin receptor protein) or genes involved in glucose homeostasis (e.g. glucose 
transporters or enzymes such as glucokinase).   In contrast, the positional cloning approach 
evaluates genes based on their physical location in the genome alone, independent of their 
function. To date, the candidate gene approach has identified several genes that are involved in 
the etiology of T2D susceptibility: INSR (insulin receptor) 14, IRS1 (insulin receptor substrate 1) 
15, PPARG (peroxisome proliferator-activated receptor gamma) 16, PTPN1 (protein tyrosine 
phosphatase 1) 17 and ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase family 
member 1) 10.     
 
1.4 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) downregulates insulin signaling 
by inhibiting insulin-receptor tyrosine kinase activity 18. In addition, ENPP1 has been shown to 
be involved in regulation of adipocyte maturation and highly regulated during adipogenesis  thus 
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suggesting a role of  insulin resistance in the absence of obesity 19. The gene that codes ENPP1 
spans over 83 kb and is located on chromosome 6q22-23.  Previous studies of variant rs1044498, 
located in exon 4 which causes an amino acid change from lysine to glutamine at codon 121 
(K121Q) 20, has shown positive associations with diabetes 21,22 23-26, insulin resistance 27, glucose 
homeostasis 28, metabolic syndrome 29, obesity 30-32 and diabetic nephropathy 33-35. However, 
negative association results question the reproducibility of these positive findings 36-38. In support 
of a potential role of ENPP1 and diabetes risk, functional studies have demonstrated that 
mutations in the gene result in overexpression of the glycoprotein leading to decreased insulin 
receptor tyrosine kinase activity 39-41.  
 
1.5 SINGLE NUCLEOTIDE POLYMORPHISMS 
Association studies do not require the analysis of large pedigrees and are generally conducted in 
affected and unaffected (case-control) sample populations.  These studies compare the 
prevalence of genetic markers, usually single nucleotide polymorphisms (SNPs), to determine if 
there is a statistically significant difference in the number of observed alleles for a marker in 
cases (affected individuals) as compared to controls (unaffected individuals).  SNPs are mostly  
commonly used in genetic association studies because they occur more frequently in the human 
genome as compared to other polymorphisms such as microsatellites and insertions/deletions.  
Although humans are roughly 99.9% identical, SNPs with a minor allele frequency greater than 
10% are present approximately every 600 base pair in the human genome 42.  Due to the 
collaborative efforts in human genetics research, databases such as NCBI’s dbSNP and the 
International HapMap project, provide data for more than 10 millions SNPs. 
 
5 
 
The goal of the international HapMap project is to provide a catalog of the common genetic 
variants in humans.  In 2001, the HapMap project released its phase I data for over 1 million 
SNPs 43, with hopes of genotyping and releasing data for 4.6 million additional SNPs in phase II 
of the project.  The HapMap project provides genotypic data for four ethnically diverse 
populations.  These populations include 90 Yoruban individuals (thirty trios) from Ibadan, 
Nigeria (YRI), 45 unrelated Japanese individuals from Tokyo, Japan, 45 unrelated Han Chinese 
individuals from Beijing, China, and 90 (thirty trios) United States residents from Utah (CEPH), 
with northern and western European ancestry.  The availability of SNP data from databases such 
as the International HapMap project continue to greatly advance SNP selection strategies for 
association studies in populations of all ethnicities. 
 
1.6 INTERPRETATION OF ASSOCIATION RESULTS 
Significant results from an association study may be interpreted several ways.  One possibility is 
that the positive association is a false positive.  False positives may arise due to poor genotyping  
quality, population substructure, or admixture.  A second alternative possibility may be that the 
association observed is a true association for which the actual causal variant for the disease is the 
variant being analyzed.  This could be a result of an effective SNP selection process or due to 
chance alone.  A third possibility may be that the associated SNP represents true association, 
although the genotyped SNP is in linkage disequilibrium (LD) with the actual causal variant.  
 
1.7 LINKAGE DISEQUILBRIUM AND HAPLOTYPES 
Linkage Disequilibrium (LD) is defined as the non-random assortment between alleles at two or 
more loci.  In other words, markers are considered to be in LD when an allele at one locus is 
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found together with an allele at a second locus more often than if they were segregating 
independently.  Generally LD will be greater if the loci are in close proximity to one another, 
although LD may be observed for SNPs separated by large distances.  The extent of LD varies 
across the genome as well as from one ethnic group to another, as described by Gabriel et al, 
2002, where they noted that the mean block size in Yoruban Nigerians and African American 
samples was 11 kb, compared with 22 kb observed in European and Asian samples.  LD block 
size varied from <1 to 94 kb in the Yoruban Nigerians and African Americans and <1 to 173 kb 
in the Europeans and Asians 44. 
 
1.8 ADMIXTURE 
Association studies of unrelated individuals are widely used in order to identify susceptibility  
loci; even though it is not usually addressed, population substructure can produce false  
association results.  Admixture is defined as the intermixing of once isolated populations 45.  In 
the U.S., African Americans and Hispanic Americans are the two largest admixed populations.  
Genetic studies in admixed populations such as Hispanic populations and African American are 
presented with the challenge of addressing the contributions due to admixture.    In order to 
estimate the genetic contribution of ancestral populations to admixed individuals or populations 
one can use genetic markers known as ancestry informative markers (AIMs) 46.  AIMs have also 
been used to determine whether a given trait is associated with ancestral proportions.   
Addressing population substructure is necessary for tests of genetic association in order to 
account for spurious associations.  
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2.0 GOALS AND SPECIFIC AIMS 
 Although diabetes is a growing epidemic in the African American community, there are few 
research efforts/projects that address the genetic contributions to the disease in populations with 
very little admixture.   The overall goal of this project explores possible genetic mechanisms of 
the ENPP1 gene with diabetes and glycemic related traits in an Afro Caribbean population from 
Tobago. The working hypothesis of this study was that the candidate gene approach would 
successfully identify variants in ENPP1 that contribute to these diseases with complex etiologies.  
Elucidation of genetic components of diabetes is anticipated to drive efforts toward a 
mechanistic understanding of the disease and its complications.  
 
2.1 SPECIFIC AIM 1:  TO COMPREHENSIVELY INVESTIGATE ENPP1 
VARIANTS FOR ASSOCIATION WITH BODY MASS INDEX, FASTING GLUCOSE, 
FASTING INSULIN AND INSULIN RESISTANCE IN NON-DM CONTROLS. 
We aim to replicate positive association results in a subset of Afro-Caribbean controls from the 
Tobago Health Study Cohort, consisting of 1,454 healthy individuals. 
 
2.2 SPECIFIC AIM 2: EVALUATE K121Q VARIANT AND COMMON ENPP1 
VARIANTS FOR ASSOCIATION WITH T2D. 
We will use existing data. SNPs will be genotpyed in 384 diabetic (cases) individuals and 1454 
healthy (controls) individuals African origin men aged 40+ in the Tobago Health Study Cohort 
and analyzed for single SNP genotypic association. The most strongly disease-associated 
variant(s) will be identified.  
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3.0 RESEARCH DESIGN AND METHODS 
3.1 STUDY POPULATION 
Three-thousand two-hundred men aged ≥40 years were recruited on the Caribbean island of 
Tobago between 1998 and 2003 for a population-based prostate specific antigen screening study 
among previously unscreened men 47. The population is predominantly of West African origin.  
Ancestry informative molecular markers have estimated 94% African, 4.6% European and 1.4%  
Native American ancestry in this population 48. In brief, recruitment was accomplished by word 
of mouth, hospital flyers and radio broadcasting. To be eligible, men had to be 40 years and 
older, ambulatory and not terminally ill. Approximately 60% of all age-eligible men on the 
island participated and participation was similar across the island Parishes.  Questionnaires were 
administered to obtain information on demographic characteristics, occupation, medical history, 
and lifestyle related factors. All men who participated in the baseline exam were invited to 
participate in a follow-up clinic exam between 2004 and 2007 and 2,031 men in the cohort (70% 
of survivors) and 451 new participants completed the visit. Written informed consent was 
obtained using forms approved by the Institutional Review Boards of the University of 
Pittsburgh and the Tobago Ministry of Health. 
 
3.2 BLOOD SAMPLE COLLECTION AND GLUCOSE MEASUREMENT 
Blood samples were obtained by venipuncture in the morning after a 12-h fast and stored at –80 
°C until assays were completed. Serum glucose was measured by using an enzymatic procedure 
49. An RIA procedure developed by Linco Research, Inc. was used to measure insulin. To 
quantify insulin resistance we used the homeostatic model assessment (HOMA) equation (fasting 
glucose * fasting insulin/22.5) 50.  
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3.3 SNP SELECTION  
We used a two-stage strategy to prioritize SNPs for genotyping. First, we employed a tagging  
SNP approach to capture common genetic variation across the ENPP1 gene region. We initially  
identified 149 SNPs across the ENPP1 gene region (including 10kb downstream and 10kb 
upstream of the transcript) using publicly available SNP data from Phase II of the International 
HapMap project (http://www.hapmap.org) that were obtained using samples from the Yoruban 
(YRI) population in Ibadan, Nigeria. A subset of informative SNPs was then selected from this 
larger reference SNP panel using a pair-wise correlation method with r2 ≥0.80 and minor allele 
frequency (MAF) ≥0.05 using the program HClust 51. Using this approach, we identified 52 
SNPs (36 singletons and 16 tagging SNPs) from the 91 SNPs in the reference SNP panel that had 
a MAF≥0.05. We then used the Function Analysis and Selection Tool for Single Nucleotide 
Polymorphisms (FASTSNP) (http://fastsnp.ibms.sinica.edu.tw) 52 and the ElDorado tool (version 
4.5) from the Genomatix software package (Genomatix Suite release 3.4; 
http://www.genomatix.de) to prioritize the 36 singleton SNPs for genotyping based on their 
predicted functional effects.  FASTSNP identifies SNPs that may alter: 1) the amino acid 
sequence of the encoded protein to one with different structural characteristics or a premature 
termination of an amino-acid sequence; 2) an exonic splicing enhancer/silencer binding site in a 
coding sequence that may affect splicing regulation; 3) a consensus splicing site sequence; 4) a 
putative binding site for a transcription factor in the promoter or an intronic enhancer region; or 
5) a 3’ untranslated region motif likely to be involved in post-transcriptional regulation. The 
ElDorado tool was used to identify SNPs that may create or abolish a putative transcription  
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factor binding site in the promoter/regulatory region of genes. Singleton SNPs that were not 
predicted to be potentially functional were not genotyped.  This approach yielded a total of 38 
SNPs (4 SNPs in promoter region, 1 intergenic, 2 coding, 2 intron boundary, 26 non-coding and  
3 in the 3’UTR). Average SNP density was 1 SNP every 3.3 kb, with the largest gap 19.6 kb and  
the smallest 55 bp.  
 
3.4 DNA EXTRACTION AND GENOTYPING 
Genomic DNA was extracted from 5 ml frozen blood clots (baseline sample) or whole blood 
(follow-up) using the Qiagen DNA Blood Kit (Qiagen, Inc., Valencia, CA). One hundred 
nineteen bi-allelic Admixture Informative Markers (AIMs), were selected to maximize European 
and African allele frequency differences 53. PCR primers were purchased from Invitrogen 
(Carlsbad, CA) and genotyping was performed using Sequenom MassARRAY iPLEX Gold 
technology (Sequenom, Inc; San Diego, CA). The average genotyping completeness rate was 
96.3%. The average genotyping consensus rate among ~7% blind replicate samples was 98.4%. 
 
Genotyping of ENPP1 SNPs was performed using pre-designed TaqMan SNP genotyping assays 
(Applied Biosystems). Genotyping was completed according to the manufacture’s protocol on a 
7900HT Fast Real-Time PCR system (Foster City, CA). The reactions were cycled with standard 
TaqMan conditions (50°C for 2 min hold, 95°C for 10 min hold, 95°C for 15 sec and 60°C for 1 
min for 40 cycles and then cool down to 4°C). The genotypes were called with the Applied 
Biosystems SDS 2.2.2 software package. Final genotyping results were evaluated manually by  
11 
 
two trained technicians who were blinded to case-control status. Four SNPs (rs9493105, 
rs7773477, rs9493116 and rs9402345) were dropped from further analysis due to low 
genotyping success rates. Our final marker set consisted of 34 SNPs. The average genotyping  
completeness rate was 95.9%. The average genotyping consensus rate among 5% blind replicate 
samples was 99.4%. Using the program Tagger, we estimate that the 34 genotyped SNPs 
captured 77% of the common variation in the ENPP1 gene region 54. 
 
3.5 STATISTICAL METHODS 
Characteristics of cases and controls were tested for significant differences using unpaired 
Student’s t-tests. Hardy-Weinberg equilibrium (HWE) was assessed using the χ2 goodness-of-fit 
statistic (P ≤0.001).  Haplotype block structure was established using Haploview 4.2 55, using the 
block definition from Gabriel et al.56. Haplotype frequencies were estimated using the EM 
algorithm implemented in the software program Dandelion 3.0 using a permutation test of the 
multinomial likelihood ratio statistic using 1000 permutations 57. 
 
To model population substructure and obtain a multidimensional ‘ancestry’ score for each 
individual, principal component analyses which is especially sensitive to subtle population 
structure was used 58-61.  Eigenvectors was developed from these SNPs and plotted against each 
other to evaluate substructure and outliers. Our experience with black populations after removal 
of ‘outlier’ indicates that 2-3 PCs are sufficient, especially to distinguish between ethnic groups. 
The present analysis is limited only to men at the follow-up visit with the comprehensive data on  
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fasting glucose and insulin and who were not outliers based on 130 African Ancestry informative 
molecular markers (N=120).  Among these men, 380 had diabetes defined as a fasting serum 
glucose concentration ≥126 mg/dL or current use of antidiabetic medication and 1,455 Afro- 
Caribbean controls without a current diagnosis of diabetes were used for the current analysis. 
Tests of association under the three a priori genetic models (additive, dominant, and recessive) 
are reported. Due to a lack of validity of the large sample χ2 test statistic, only the dominant 
model was considered for SNPs with ten or fewer individuals that were homozygous for the 
minor allele. Quantitative traits (insulin, and homeostatic model assessment of insulin resistance 
(HOMA-IR)) association analysis for every SNP in the control population was performed using a 
series of analysis of variance (ANOVA) tests implemented in QSNPGWA 62. 
Unadjusted odds ratios (ORs) and 95% confidence intervals (CI) in the case-control sample were 
computed using SNPGWA to test all SNPs for genotypic association with diabetes 63.  
 
 SNPs that showed nominal evidence for association were further adjusted for age- and body 
mass index (BMI).  A P value of <0.05 was considered significant. All adjusted multivariable 
linear regression and unconditional logistic regression analyses were performed using Stata 10 
(College Station, TX).  
3.5.1 Correction for multiple testing 
To correct for multiple tests at the gene level the conservative Bonferonni method was used, with 
a P-value <0.0004 considered significant evidence for association when assuming independence 
based on linkage disequilibrium (LD).  
 
 
13 
 
4.0 RESULTS 
4.1 POPULATION CHARACTERISTICS 
Baseline characteristics of the Afro-Caribbean cases and controls are summarized in Table 1. 
The mean age of examination for the non-diabetic controls was 5 years younger than the mean 
age of those with diabetes (P<0.0001). Additionally, the diabetes cases were more insulin 
resistant and hyperglycemic (166.6±67.4 vs. 91.7±11.6) compared to non diabetic controls 
(P<0.0001).  
4.2 SNP ASSOCIATION ANALYSES 
4.2.1 Hardy-Weinberg Equilibrium and linkage disequilibrium 
The genotypic distribution of all ENPP1 variants in cases and controls was in Hardy-Weinberg 
equilibrium (all P > 0.001). The linkage disequilibrium (LD) structure present in controls (Figure 
1) and cases (Figure 2) was compared by evaluating the total number of blocks and average 
block size (kb) between cases and controls.  Using the Confidence Interval method 56 
implemented in Haploview (with default settings), there were 9 blocks in cases (average block 
length 2.9 kb) and 9 LD blocks in controls (average block size of 2.8kb). Figures 1 and 2; 
respectively. 
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Figure 1.   Linkage Disequilibrium Structure of ENPP1 in Afro-Caribbean Controls (n=1,455). LD 
determined using Confidence Interval method 56 implemented in Haploview 4.2 (with default settings), 
with blocks extended if pairwise D’ > 0.80.  Red squares indicate high pairwise LD (D’ = 1.00), gradually 
coloring down to white squares of low pairwise LD. 
 
 
 
Figure 2.   Linkage Disequilibrium Structure of ENPP1 in Afro-Caribbean Cases (n=380). LD 
determined using Confidence Interval method 56 implemented in Haploview 4.2 (with default settings), 
with blocks extended if pairwise D’ > 0.80.  Red squares indicate high pairwise LD (D’ = 1.00), gradually 
coloring down to white squares of low pairwise LD.   
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4.2.2 Association Analyses with Analyses with BMI in Controls 
One intron 1 SNP rs703184 were nominally associated with higher BMI (Table 2). SNP 
rs703184 was nominally associated with higher BMI (30.6±10.5 kg/m2 for “CC” genotype 
compared with 27.1±4.5 kg/m2 for “GG”/“GC”; age-adjusted P=0.006).  In contrast, rs1044498 
(minor “A” allele corresponding to the K121 allele) was nominally associated with lower BMI 
(25.9±3.9 kg/m2 for “AA” genotype compared with 27.2±4.6 kg/m2 for “CC”/“CA”; age-adjusted 
P=0.018).  Detailed association results for BMI are presented in Table 4.  
 
4.2.3 Association Analyses with Analyses with Glucose in Controls 
Six SNPs showed nominal evidence for association with fasting glucose in one or more 
genotypic model (Table 2). Four intronic SNPs (rs858345, rs6569759, rs1830971, rs1409181, 
rs17060836) and rs7768480, located in intron 20–exon 21 boundary (age-and BMI adjusted P 
values ranging from 0.001 to 0.020). The most significant association was observed for 
rs6569759, located in intron 1 being associated in all three genotypic models (age-and BMI 
adjusted P = 0.003, 0.001, 0.009 for the dominant, additive, and recessive models. Further results 
for glucose are presented in Table 5. 
 
4.2.4 Association Analyses with Insulin Levels and Insulin Resistance Estimated  
by HOMA in Controls 
Association analyses revealed one SNP nominally associated with insulin resistance estimated by 
HOMA-IR and two SNPs associated with fasting insulin levels (Table 2). The homozygote 
recessive genotype (“TT”) for SNP rs858345, located in intron 1, was nominally associated with 
decreased insulin resistance (unadjusted P=0.043). The most significant association was between 
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insulin and SNPs rs6935458 and rs9372999, located in the promoter region and intron 1, 
respectively. As shown in Table 2, rs9372999 was nominally associated with increased fasting 
insulin (13.3±8.4 μU/ml for recessive “AA” genotype compared with 12.2±6.9 μU/ml) for 
“CC”/“CA”; P=0.044).    In contrast, SNP rs6935458 was nominally associated with lower 
fasting insulin (dominant P=0.033; 11.6±5.9 μU/ml for the “AA” genotype vs. 12.2±6.4 μU/ml 
for the “AG”/“GG” genotypes). Association results for insulin levels and insulin resistance are 
presented in Tables 6 and 7; respectively. 
 
4.2.5 Association Analyses with Type 2 Diabetes 
Genotypic associations (P≤0.05) were observed with SNPs rs703184 (dominant P=0.022, 
adjusted Pa =0.068); rs7749493 (dominant P=0.037, Pa =0.025; additive P=0.019, Pa =0.014), 
rs17060836 (dominant P=0.020; Pa =0.019), rs7754561 (dominant P=0.020, Pa =0.034); 
rs776993 (dominant P=0.025; Pa =0.032) and rs9373000 (dominant P=0.008, Pa =0.012; 
additive P=0.018, Pa=0.023 ). Single-SNP genotypic association results are presented in Table 8. 
Genotype frequencies and counts for each SNP are shown in  Table 9.  
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5.0 DISCUSSION 
We examined the association of common variants in ENPP1 with BMI, glycemia traits and 
diabetes prevalence in an Afro-Caribbean population at high risk of diabetes 64. We found that 
the widely studied rs1044498 minor K121 allele was associated with lower BMI among non-
diabetic controls.  In addition, we found that variants in intron 1 and the 3’UTR were associated 
with diabetes independent of age and BMI. Our findings confirm and extend previous reports of 
associations between common variants in ENNP1 with obesity and diabetes.   
 
Two reports to date have shown that the Q121 genotype is associated with lower BMI in non-
diabetic populations of European and  African American populations 26,65 whereas others have 
reported that the Q121 genotype is associated with higher BMI 66,67.  Given the discordant 
genotypic association between rs1044498 (K121Q) and BMI our association of K121 in our 
study population with lower BMI might be attributable to differences in genetic backgrounds 
between these populations. 
 
The allele frequency of the minor K121 allele of rs1044498 in Afro-Caribbean controls (0.14) 
closely resembles the frequencies of the HapMap YRI (0.08) and previously reported African-
American control and case subjects 23,25,26.  However, the frequency in the Afro-Caribbean 
Dominican Republic population (0.46) is dramatically higher which may reflect a higher degree 
of European admixture in this cohort than in the HapMap Nigerian population or our Afro-
Caribbean population of Tobago 24.  
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Nominal associations with intron 1 SNPs (rs6569759, rs1830971, rs1409181, rs858345) were 
observed with fasting glucose (Table 2).  Jenkinson, et al. 68, identified four SNPs (rs1800949, 
rs6918013, rs7756163, rs7754609) spanning  intron 1 associated with fasting glucose in 
nondiabetic Mexican Americans from the San Antonio Family Diabetes Study (SAFDS) with P-
values ranging from 0.0047-0.048.  Bochenski 69 et al., revealed that rs997509, also located in 
intron 1is not associated with diabetes in nonobese individuals from Poland, although 
nonsignificant (P>0.40) there is a 32% decreased risk of diabetes.  However in obese subjects, 
rs997509 was found to be associated with a 4.7 fold increased risk of diabetes 69. These 
observations suggest that polymorphisms in this region of ENPP1 may be heterogeneous and 
further exploration of the region is required. 
 
Modest association with diabetes was detected with two intron 1 variants (rs703184 and 
rs7749493), an intron 11 variant (rs17060836) and three variants located in the 3’untranslated 
region (UTR) (rs7754561, rs7769993 and rs9373000).  Men having at least one copy of the 
major allele for rs7749493 and rs7754561 had a 21 to 31% decreased risk of diabetes. In 
contrast, the major alleles for SNPs rs703184, rs17060836, rs9373000 and rs7769993 were 
associated with an increased risk of diabetes with ORs between 1.33-1.39. After adjusting for 
age and BMI, associations with all SNPs except rs703184 remained nominally significant. 
Additionally, haplotype analysis showed nominal evidence of association with 2 three-marker 
haplotypes (Supplementary Table 7). The three-marker haplotypes are located in the promoter 
region and the 3’UTR, with P values from 0.034 to 0.039; respectively.  
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In a recent report by Keene et al. 25 rs7754586 located approximately 48bp – 8.9 kb away from 
rs7754561, rs7769993 and rs9373000 was associated with increased diabetes risk (OR ranging 
from 1.34-1.50)  in 577 African American cases with diabetes-end stage renal disease and 596 
African American controls. Functional studies of a cluster of SNPs (rs1044548, rs11964389 and 
rs1044558) which make up a 3-SNP haplotype located in the 3’UTR performed by Frittitta et al. 
41 demonstrated that chinese hamster ovary (CHO) cells transfected with the 3-SNP haplotype 
revealed overexpression of ENPP1 protein due to increased mRNA stability. We did not directly 
investigate these markers in our Afro-Caribbean population due to our SNP selection process. 
However, markers rs7754561, rs7769993 and rs9373000 fall within one 15 kb block of high LD 
consisting of 37 HapMap SNPs spanning the 3’ UTR.  
 
The replicated K121Q (rs1044498) SNP in European populations 67,70-72was analyzed in our 
case-control population, however it was not associated with diabetes (P values ranging from 
0.079 to 0.792). Although nonsignificant, the trend for rs1044498 risk is in the direction and the 
OR close to reported values in African Americans as reported by Keene et al. 23,25,26.  
 
ENPP1 is known to have potential pleiotropic effects on obesity and diabetes 73 thus; we 
performed our analyses with and without adjustments for BMI. We found that adjustments for 
BMI reduced the strength of the observed association between rs858345 with HOMA-IR and 
rs6935458 and rs9372999 with insulin.   However, associations between several ENNP1 SNPs 
with diabetes remained nominally significant after adjusting for age-and BMI. This observation 
suggests that at least some of the potential effect of ENPP1 variants on diabetes susceptibility  
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may be mediated through mechanisms independent of obesity.  Indeed, there is evidence that 
ENPP1 has a direct role in insulin signaling and insulin sensitivity 74.  We corrected our 
associations for multiple comparisons using the conservative Bonferroni method assuming 
independence based on LD. Although our study is the largest to date on ENPP1 and obesity and 
diabetes related measures in African ancestry individuals, none of the nominally significant 
associations surpassed the conservative Bonferonni threshold (P<0.0004).  Larger studies of 
ENPP1 in African ancestry individuals will be needed to replicate and extend our findings in this 
population group. 
 
Overall, this study supports an association of the widely studied and replicated ENPP1-
rs1044498 variant with lower BMI 65. In addition, our analysis identified and confirmed 
associations with common variants in the 3’UTR with diabetes 25. Denser SNP genotyping and 
direct sequencing along with functional studies investigating the 3”UTR of the ENPP1 gene 
merits further examination to investigate the biological relevance of variations in this region. 
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6.0 CONCLUSIONS AND PUBLIC HEALTH RELEVANCE 
 
 
The ENPP1 gene was analyzed for association with T2D-ESRD in this study.  To 
comprehensively evaluate variants in ENPP1 for association with T2D-ESRD, 34 SNPs located 
in the coding and flanking regions of ENPP1 were successfully genotyped in 380 Afro-
Caribbean men with diabetes and 1,455 men without diabetes.  Positive association was detected 
with eight SNPs, one located in exon 4, two in intron 1, one in intron 11 variant and three 
variants located in the 3’UTR.  Seven of the associated SNPs had not been reported in diabetes 
and diabetes related association studies of ENPP1.   
 
The close proximity of the two most significantly associated SNPs  in the 3’UTR are in high LD 
(r2 = 0.98) and the prior identification of variants in 3’UTR provide evidence that variants in the 
distal region of ENPP1 are important in relation to diabetes susceptibility in African ancestry 
population. 
 
The contributions of associated SNPs have not been fully examined.  Due to the frequency and 
overall odds ratio, it appears that these SNPs would only modestly account for the disparity of 
T2D.  These findings, coupled with the linkage data in African Americans 75, insulin levels, 
insulin resistance, and leptin concentrations 69 76, support a possible pleiotropic effect for variants 
in ENPP1. 
 
Additionally, addressing the confounding affects of admixture in genetic association studies of is 
very important.  Through the use of ancestry informative markers, this study has presented the  
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first exploratory analysis of the impact of admixture in studies of Afro-Caribbean. This supports 
the use of ancestral proportions as a means of reducing spurious associations due to admixture.  
Several studies have tested for association with markers for ancestry and ancestral estimates 77-80 
, however it appears that only one study (outside of our laboratory) has performed admixture 
adjustments for genetic association studies 81.   
  
Over the last few years and during the span of this project, several advances and findings have 
been reported in the field of diabetes genetics.  The recent use of Genome Wide Association 
Studies (GWAS) has overshadowed the traditional approach of linkage analysis for identifying 
genes.  Although both approaches have their pros and cons, there is a growing trend towards 
GWAS in case-control populations as opposed to linkage analysis in families.  The combined 
efforts of both approaches has led to the identification of several significant associations, 
however the reproducibility of the most of those associations are questionable.  To date, there are 
8 or so genes that are widely accepted in the diabetes genetics research community as “T2D 
genes.”  These genes include peroxisome proliferator-activated receptor γ (PPARG) 16, ATP-
sensitive inwardly-rectifying potassium channel subunit Kir6.2 (KCNJ11) 82, transcription factor 
7-like 2 (TCF7L2) 83, solute carrier family 30 member 8 (SLC30A8) 84-87, CDK5 regulatory 
subunit associated protein (CDKAL1) 84,86-89, insulin-like growth factor 2 mRNA binding protein 
(IGF2BP2) 84,86,87,89, and the region encoding cyclin-dependent kinase inhibitor 2A and cyclin-
dependent kinase inhibitor 2B (CDKN2A/CDKNA2B) 84,87,89.  Outside of PPARG, KCNJ11, and 
TCF7L2, the majority of these findings (five) were identified using GWAS, many of which have 
been confirmed across several studies. 
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These finding suggest that positive associations observed in Europeans do not necessarily hold 
true in populations of African descent and variants unique to populations of African descent 
probably exist. Although TCF7L2 associations have been replicated across numerous 
populations, the mechanism behind the association is not fully understood. 
 
In conclusion, with the increasing number of genes identified that contribute to T2D, replication 
studies across several populations and ethnicities are necessary to confirm findings.  Due to the 
increased genetic diversity (i.e. more variants and less LD) for African derived populations as 
compared to populations of European descent, it is possible that some of the significant 
associations observed in European populations may not hold true in African ancestry genetic 
association studies.  Current GWAS in Europeans capture approximately 78% of the common 
SNPs, defined as having a MAF>5% in HapMap CEU, but the same SNP set would capture less 
variation in African populations.  Until funding (and adequate SNP sets) for large scale GWAS 
as well as sequencing efforts in African populations are available, positional cloning approaches, 
candidate gene studies, and mapping by admixture linkage disequilibrium (MALD) provide the 
most productive avenue for identifying genes that contribute to diabetes and/or related traits.  
These studies, however, must incorporate a well characterized, adequately powered sample size 
sufficient to detect true associations, thorough SNP coverage across genes, and take into account 
any influences due to admixture.  In my opinion, the successes reported from GWAS will 
ultimately trigger a paradigm shift in the field away from a focus on identifying genes, and 
instead towards determining the mechanisms and functions of variants in those genes. 
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We anticipate with the increasing number of genetic information obtained via the use of dense 
genetic information this will lead to the need for larger and more in-depth study of this topic.  
The information obtained will aid to advance the care of populations of African ancestry affected 
and those at risk of T2D. As public health has shown mortality and morbidity of T2D is higher in 
populations of African descent. T2D is a major health issue whose risk factors include older age, 
obesity, ethnicity and family history.  Gene identification remains a daunting task while the next 
challenge is the identification of genes and genomic regions responsible for gene regulation. 
Knowledge along with each gene function and gene regulation is expected to be the cornerstone 
for the development of new drugs and improved treatment. As genetic information becomes 
more involved in medical practice, (i.e personalized medicine) knowing ones genetic makeup 
can aid in therapeutic strategies, disease prevention, etc. Thus the identification of genes will 
significantly benefit public awareness and public health (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Progression and Direction for Genomic Studies and their Implications 
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APPENDIX: TABLES 
 
Table 1. Characteristic of the Afro Caribbean Men  
Trait 
T2D Cases Controls 
(n=380) (n=1454) 
   
Age at exam (years±SD) 62.8±10.2 57.9±10.1‡ 
BMI (kg/m2) 28.4±5.6 27.1±4.6‡ 
Insulin (ìU/ml) 13.2±8.4 12.0±6.2† 
Glucose (mg/dl) 166.6±67.4 91.7±11.6‡ 
HOMA-IR 5.3±3.6 2.8±1.5‡ 
 
Mean differs significantly between cases and controls P-value ‡<0.001 and † <0.05.
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Table 2. Nominally Significant (P<0.05) Single-SNP Genotypic Tests of Association with BMI, Fasting Glucose, Insulin 
Resistance using HOMA-IR and Fasting Insulin in Non-Diabetic Controls. 
 
Phenotype Marker Location 
Major†/       
Minor 
alleles 
MAF 
Controls 
*1/2 1/1 1/2 Additive Dominant Recessive 
Mean ± SD Mean±SD Mean ±SD P-value P-value P-value 
BMI rs703184 Intron   G\C 0.09 26.9±4.4 (221) 27.2±4.5 (1150) 30.6±10.5 (13) 0.511 0.982 
0.007 
(0.006)a 
BMI rs1044498 Exon C\A 0.14 27.0±4.6 (302) 27.2±4.5 (1036) 25.4±3.8 (38) 
0.040 
(0.066) a 0.147 
0.013 
(0.018) a 
Glucose rs6569759 Intron  1 G\A 0.24 90.9±11.8 (485) 92.5±11.7 (809) 94.8±9.9 (88) 
0.0005 
(0.001) 
0.002 
(0.003) 
0.010 
(0.009) 
Glucose rs858345 Intron   C\T 0.36 91.8±11.8 (591) 92.1±11.6 (562) 89.3±11.4 (179) 0.085 0.611 
0.006 
(0.012) 
Glucose rs17060836 Intron   T\C 0.23 92.4±12.1 (464) 90.3±11.1 (814) 92.1±11.6 (76) 
0.029 
(0.018) 
0.004 
(0.002) 0.742 
Glucose rs7768480 
Intron 
(boundary) G\A 0.46 91.4±11.9 (670) 91.3±11.7 (418) 93.0±11.3 (301) 0.094 0.551 
0.025 
(0.019) 
Glucose rs1830971 Intron   A\G 0.26 91.8±11.5 (526) 91.9±12.0 (747) 88.9±10.9 (100) 0.161 0.601 
0.016 
(0.005) 
Glucose rs1409181 Intron   C\G 0.31 91.9±11.5 (568) 91.9±11.9 (662) 89.5±10.9 (141) 0.121 0.499 
0.022 
(0.020) 
Insulin rs6935458 Promoter A\G 0.43 12.1±6.4 (639) 11.6±5.9 (468) 12.6±6.6 (268) 0.063 
0.033 
(0.108) b 0.102 
Insulin rs9372999 Intron   C\A 0.26 11.9±6.6 (490) 11.9±5.8 (743) 13.3±8.4 (106) 0.497 0.169 
0.044 
(0.264) b 
HOMA-IR rs858345 Intron   C\T 0.36 2.8±1.6 (591) 2.8±1.6 (562) 2.5±1.2 (179) 0.350 0.937 
0.043 
(0.205) b 
 
Test models refer to the minor allele.  *1= Major Allele; 2= Minor Allele in Controls.  Bold: P-values <0.05.  Unadjusted P values 
without parentheses and P values with parentheses adjusted for (a) Age; (b) Age- and BMI  
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Table 3 Nominally Significant (P<0.05) Single-SNP Genotypic Tests of Association with Type 2 Diabetes. 
 
Locations Marker 
Major†/   
Minor 
alleles 
Dominant* 
P-value OR (95% CI) 
Additive          
P-value OR (95% CI) 
Recessive 
P-value OR (95% CI) 
Intron   rs703184 G\C 0.022 (0.068) 1.39 (1.05-1.85) - - - - 
Intron   rs7749493 G\T 0.037 (0.025) 0.78 (0.61-0.99) 
0.019 
(0.014) 0.79 (0.65-0.96) 0.095 0.64 (0.38-1.08) 
Intron   rs17060836 T\C 0.020 (0.019 ) 1.32 (1.04-1.67) 0.092 1.18 (0.97-1.43) 0.562 0.85 (0.50-1.46) 
3’UTR rs7754561 G\A 0.020 (0.034) 0.70 (0.52-0.95) - - - - 
3’UTR rs7769993 A\G 0.025 (0.032) 1.33 (1.03-1.71) 0.249 1.10 (0.93-1.30) 0.533 0.91 (0.67-1.23) 
3’UTR rs9373000 A\G 0.008 (0.013) 1.38 (1.08-1.76) 
0.018 
(0.023) 1.22 (1.03-1.44) 0.339 1.17 (0.85-1.62) 
 
*Only the dominant model was considered where the minor allele homozygote count for either cases or controls was <10.  Test 
models refer to the minor allele.  †Major allele is defined as most common allele in controls.  ‡Dominant model.  Bold: P-values 
<0.05. Unadjusted P values without parentheses and P values with parentheses adjusted for age- and BMI.  
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Table 4. Single SNP Association Results for BMI (kg/m2) 
 
Marker Position Location 
Major†/ 
MAF 
Controls 
*1/2 1/1 2/2 Additive  Dominant  Recessive 
Minor 
alleles Mean±SD Mean ± SD Mean ±SD P-value P-value P-value 
rs7773292 132141454 
 
C\T 0.22 27.3±4.0 (430) 27.1±4.9 (814) 27.2±4.4 (79) 0.687 0.635 0.958 
rs6925433 132161059 Promoter A\G 0.19 27.4±4.4 (406) 27.1±4.7 (885) 26.5±3.9 (48) 0.870 0.541 0.286 
rs13211931 132165417 Promoter G\T 0.09 27.1±4.7 (207) 27.2±4.6 (1150) 27.4±3.3 (17) 0.813 0.747 0.842 
rs6935458 132168013 Promoter A\G 0.43 26.9±4.8 (639) 27.1±4.4 (468) 27.6±4.5 (268) 0.233 0.769 0.071 
rs6936129 132168133 Promoter G\C 0.09 27.3±4.8 (223) 27.2±4.6 (1104) 26.8±3.3 (16) 0.735 0.641 0.743 
rs6569759 132174809 Intron   G\A 0.24 27.3±4.9 (485) 27.2±4.4 (809) 26.6±4.5 (88) 0.618 0.957 0.253 
rs6939185 132180880 Intron   G\A 0.09 27.2±5.1 (228) 27.1±4.5 (1161) 26.6±5.7 (15) 0.988 0.885 0.636 
rs9398995 132181896 Intron   T\C 0.22 27.0±4.4 (443) 27.3±4.7 (849) 26.8±4.3 (75) 0.268 0.305 0.474 
rs943004 132182569 Intron   C\T 0.22 27.0±4.7 (483) 27.1±4.6 (832) 27.3±4.1 (62) 0.874 0.757 0.775 
rs1830971 132190046 Intron   A\G 0.26 27.0±4.5 (526) 27.2±4.6 (747) 27.5±5.0 (100) 0.810 0.876 0.379 
rs1409181 132190993 Intron   C\G 0.31 27.1±4.4 (568) 27.2±4.6 (662) 27.1±4.8 (141) 0.649 0.649 0.806 
rs2021966 132192132 Intron   A\G 0.30 27.1±4.4 (575) 27.2±4.7 (677) 27.2±4.8 (123) 0.945 0.824 0.815 
rs7771841 132192798 Intron   G\A 0.22 27.2±4.4 (457) 27.1±4.5 (846) 27.7±4.5 (68) 0.309 0.441 0.305 
rs9372999 132194845 Intron   C\A 0.26 27.2±4.3 (490) 27.1±4.7 (743) 27.0±4.5 (106) 0.997 0.882 0.779 
rs858338 132194900 Intron   G\T 0.12 26.9±4.5 (302) 27.2±4.5 (1070) 29.3±9.0 (19) 0.873 0.693 0.039 
rs858339 132195590 Intron   T\A 0.32 26.9±4.3 (601) 27.3±4.5 (654) 27.5±5.5 (147) 0.492 0.145 0.379 
rs703184 132196688 Intron   G\C 0.09 26.9±4.4 (221) 27.2±4.5 (1150) 30.6±10.5 (13) 0.511 0.982 0.007 
rs7775386 132198842 Intron   T\C 0.49 27.2±4.5 (650) 27.2±4.6 (373) 27.1±4.7 (338) 0.722 0.753 0.788 
rs6916495 132201958 Intron   C\T 0.11 26.7±4.6 (261) 27.3±4.6 (1092) 27.6±4.3 (23) 0.221 0.128 0.642 
rs9493110 132203671 Intron   C\T 0.24 27.2±4.5 (505) 27.1±4.7 (782) 27.4±4.6 (78) 0.457 0.487 0.651 
rs858345 132205310 Intron   C\T 0.36 27.3±4.6 (591) 27.1±4.5 (562) 26.7±4.2 (179) 0.696 0.660 0.154 
rs4141767 132206700 Intron   A\G 0.41 27.2±4.7 (654) 27.0±4.5 (485) 27.2±4.1 (226) 0.593 0.455 0.968 
rs6926970 132208983 Intron   A\C 0.21 27.2±4.7 (429) 27.2±4.6 (868) 26.4±4.5 (80) 0.454 0.810 0.154 
rs1044498 132214061 Exon C\A 0.14 27.0±4.6 (302) 27.2±4.5 (1036) 25.4±3.8 (38) 0.040 0.147 0.013 
rs7749493 132216752 Intron   G\T 0.24 27.3±4.8 (476) 27.1±4.4 (804) 26.8±4.9 (98) 0.970 0.642 0.422 
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rs17060836 132230641 Intron   T\C 0.23 27.3±4.8 (464) 26.9±4.4 (814) 27.5±4.6 (76) 0.114 0.127 0.383 
rs7769712 132235088 Intron   A\C 0.31 27.3±4.3 (560) 27.2±4.8 (632) 26.7±4.5 (137) 0.549 0.980 0.205 
rs7768480 132245125 
Intron 
(boundary) G\A 0.46 27.2±4.8 (670) 27.2±4.6 (418) 27.0±4.0 (301) 0.728 0.975 0.570 
rs12202373 132251394 Intron   T\C 0.09 27.7±4.9 (215) 27.1±4.5 (1139) 26.8±4.4 (12) 0.140 0.095 0.761 
rs9493118 132253058 Intron   C\T 0.31 27.2±4.4 (538) 27.1±4.4 (622) 27.9±6.1 (138) 0.104 0.310 0.060 
rs1804025 132253227 Exon A\G 0.23 27.0±4.7 (459) 27.1±4.3 (842) 27.7±6.2 (83) 0.582 0.936 0.215 
rs7754561 132254387 3' UTR G\A 0.13 26.9±3.9 (292) 27.2±4.6 (1019) 27.8±5.0 (30) 0.680 0.455 0.425 
rs7769993 132262945 3' UTR A\G 0.42 27.2±4.8 (641) 27.1±4.3 (489) 27.1±4.7 (257) 0.965 0.757 0.765 
rs9373000 132263399 3' UTR A\G 0.36 27.1±4.8 (620) 27.2±4.3 (575) 27.0±4.6 (185) 0.711 0.794 0.712 
 
* 1= Major Allele; 2= Minor Allele in Controls. Test models refer to the minor allele.  Bold: P-values <0.05 
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Table 5. Single SNP Association Results for Fasting Glucose (mg/dl) 
Marker Position Location 
Major†/ 
MAF 
Controls 
*1/2 1/1 2/2 Additive  Dominant  Recessive 
Minor 
alleles Mean±SD Mean ± SD  Mean ±SD  P-value P-value P-value 
rs7773292 132141454 
 
C\T 0.22 91.4±11.5 (430) 92.2±11.7 (814) 90.3±12.8 (79) 0.861 0.472 0.309 
rs6925433 132161059 Promoter A\G 0.19 91.3±11.4 (406) 92.5±12.1 (885) 91.7±14.1 (48) 0.200 0.132 0.991 
rs13211931 132165417 Promoter G\T 0.09 91.5±11.8 (207) 92.4±10.9 (1150) 91.0±9.6 (17) 0.476 0.386 0.811 
rs6935458 132168013 Promoter A\G 0.43 92.2±11.1 (639) 91.4±12.4 (468) 91.5±10.9 (268) 0.374 0.271 0.768 
rs6936129 132168133 Promoter G\C 0.09 91.9±11.5 (223) 91.3±12.5 (1104) 89.0±7.8 (16) 0.247 0.319 0.325 
rs6569759 132174809 Intron   G\A 0.24 90.9±11.8 (485) 92.5±11.7 (809) 94.8±9.9 (88) 0.0005 0.002 0.010 
rs6939185 132180880 Intron   G\A 0.09 91.3±11.8 (228) 92.6±11.1 (1161) 95.5±7.2 (15) 0.052 0.076 0.193 
rs9398995 132181896 Intron   T\C 0.22 92.1±11.6 (443) 91.4±11.8 (849) 89.7±11.4 (75) 0.064 0.125 0.116 
rs943004 132182569 Intron   C\T 0.22 92.0±11.6 (483) 91.2±11.7 (832) 92.3±12.5 (62) 0.407 0.251 0.698 
rs1830971 132190046 Intron   A\G 0.26 91.8±11.5 (526) 91.9±12.0 (747) 88.9±10.9 (100) 0.161 0.601 0.016 
rs1409181 132190993 Intron   C\G 0.31 91.9±11.5 (568) 91.9±11.9 (662) 89.5±10.9 (141) 0.121 0.499 0.022 
rs2021966 132192132 Intron   A\G 0.30 92.3±11.9 (575) 91.4±11.2 (677) 90.4±11.8 (123) 0.057 0.094 0.164 
rs7771841 132192798 Intron   G\A 0.22 91.3±11.4 (457) 92.4±12.1 (846) 91.4±12.1 (68) 0.216 0.116 0.872 
rs9372999 132194845 Intron   C\A 0.26 91.6±11.8 (490) 91.9±11.7 (743) 90.4±11.6 (106) 0.699 0.914 0.264 
rs858338 132194900 Intron   G\T 0.12 91.4±11.5 (302) 92.5±11.9 (1070) 92.2±10.7 (19) 0.175 0.152 0.852 
rs858339 132195590 Intron   T\A 0.32 91.1±11.2 (601) 92.4±12.2 (654) 91.5±11.3 (147) 0.200 0.069 0.848 
rs703184 132196688 Intron   G\C 0.09 91.6±11.6 (221) 92.1±11.8 (1150) 94.2±11.3 (13) 0.386 0.461 0.429 
rs7775386 132198842 Intron   T\C 0.49 91.9±11.8 (650) 91.8±11.6 (373) 91.1±11.5 (338) 0.312 0.529 0.298 
rs6916495 132201958 Intron   C\T 0.11 91.7±11.6 (261) 91.5±12.2 (1092) 94.1±7.7 (23) 0.793 0.995 0.337 
rs9493110 132203671 Intron   C\T 0.24 91.5±11.8 (505) 92.3±11.4 (782) 89.9±12.9 (78) 0.941 0.558 0.153 
rs858345 132205310 Intron   C\T 0.36 91.8±11.8 (591) 92.1±11.6 (562) 89.3±11.4 (179) 0.085 0.611 0.006 
rs4141767 132206700 Intron   A\G 0.41 92.1±11.5 (654) 91.6±12.1 (485) 91.6±11.1 (226) 0.545 0.463 0.853 
rs6926970 132208983 Intron   A\C 0.21 91.5±11.7 (429) 91.8±11.6 (868) 93.0±12.1 (80) 0.321 0.462 0.303 
rs1044498 132214061 Exon C\A 0.14 91.7±11.8 (302) 90.9±11.1 (1036) 93.4±12.1 (38) 0.721 0.431 0.338 
rs7749493 132216752 Intron   G\T 0.24 91.7±11.6 (476) 91.6±11.8 (804) 91.7±11.8 (98) 0.907 0.884 0.994 
rs17060836 132230641 Intron   T\C 0.23 92.4±12.1 (464) 90.3±11.1 (814) 92.1±11.6 (76) 0.029 0.004 0.742 
31 
 
rs7769712 132235088 Intron   A\C 0.31 91.9±11.4 (560) 91.5±11.9 (632) 92.0±11.6 (137) 0.822 0.634 0.769 
rs7768480 132245125 
Intron 
(boundary) G\A 0.46 91.4±11.9 (670) 91.3±11.7 (418) 93.0±11.3 (301) 0.094 0.551 0.025 
rs12202373 132251394 Intron   T\C 0.09 91.8±11.6 (215) 91.2±12.0 (1139) 88.5±9.67 (12) 0.296 0.373 0.340 
rs9493118 132253058 Intron   C\T 0.31 91.9±11.5 (538) 91.7±11.5 (622) 91.6±12.1 (138) 0.786 0.787 0.879 
rs1804025 132253227 Exon A\G 0.23 91.5±11.6 (459) 91.8±11.8 (842) 91.9±11.4 (83) 0.665 0.675 0.805 
rs7754561 132254387 3' UTR G\A 0.13 91.5±11.6 (292) 92.3±12.1 (1019) 91.8±7.6 (30) 0.381 0.329 0.947 
rs7769993 132262945 3' UTR A\G 0.42 91.6±12.1 (641) 91.7±11.3 (489) 91.9±11.5 (257) 0.785 0.874 0.759 
rs9373000 132263399 3' UTR A\G 0.36 91.7±12.1 (620) 91.8±11.4 (575) 91.4±11.5 (185) 0.809 0.928 0.720 
 
* 1= Major Allele; 2= Minor Allele in Controls. Test models refer to the minor allele.  Bold: P-values <0.05 
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Table 6. Single SNP Association Results for Fasting Insulin (μU/ml) 
 
Marker Position Location 
Major†/ 
MAF 
Controls 
*1/2 1/1 2/2 Additive  Dominant  Recessive 
Minor 
alleles Mean±SD Mean ± SD  Mean ±SD  P-value P-value P-value 
rs7773292 132141454 
 
C\T 0.22 12.5±6.6 (430) 11.8±6.1 (814) 12.2±6.7 (79) 0.118 0.194 0.894 
rs6925433 132161059 Promoter A\G 0.19 12.5±6.2 (406) 11.8±6.2 (885) 11.9±7.4 (48) 0.116 0.195 0.892 
rs13211931 132165417 Promoter G\T 0.09 11.6±5.8 (207) 12.1±6.3 (1150) 13.0±4.1 (17) 0.394 0.562 0.506 
rs6935458 132168013 Promoter A\G 0.43 12.1±6.4 (639) 11.6±5.9 (468) 12.6±6.6 (268) 0.063 0.033 0.102 
rs6936129 132168133 Promoter G\C 0.09 12.5±6.6 (223) 11.9±6.1 (1104) 12.5±5.6 (16) 0.210 0.225 0.761 
rs6569759 132174809 Intron   G\A 0.24 12.3±6.8 (485) 11.9±5.9 (809) 11.7±5.3 (88) 0.505 0.753 0.586 
rs6939185 132180880 Intron   G\A 0.09 11.9±5.2 (228) 12.0±6.4 (1161) 9.9±3.8 (15) 0.612 0.431 0.195 
rs9398995 132181896 Intron   T\C 0.22 11.7±5.8 (443) 12.1±6.3 (849) 12.4±7.1 (75) 0.441 0.672 0.595 
rs943004 132182569 Intron   C\T 0.22 12.0±6.3 (483) 11.9±6.1 (832) 13.4±8.2 (62) 0.358 0.160 0.078 
rs1830971 132190046 Intron   A\G 0.26 11.7±5.8 (526) 12.2±6.6 (747) 12.2±6.5 (100) 0.201 0.364 0.797 
rs1409181 132190993 Intron   C\G 0.31 11.9±6.4 (568) 12.2±6.3 (662) 11.9±6.1 (141) 0.410 0.438 0.736 
rs2021966 132192132 Intron   A\G 0.30 11.8±5.9 (575) 12.1±6.6 (677) 11.9±6.3 (123) 0.414 0.505 0.932 
rs7771841 132192798 Intron   G\A 0.22 12.0±5.9 (457) 12.1±6.5 (846) 11.2±4.9 (68) 0.631 0.444 0.321 
rs9372999 132194845 Intron   C\A 0.26 11.9±6.6 (490) 11.9±5.8 (743) 13.3±8.4 (106) 0.497 0.169 0.044 
rs858338 132194900 Intron   G\T 0.12 12.4±5.7 (302) 11.9±6.3 (1070) 11.5±5.1 (19) 0.311 0.399 0.734 
rs858339 132195590 Intron   T\A 0.32 11.9±5.8 (601) 12.1±6.8 (654) 11.9±5.5 (147) 0.587 0.662 0.953 
rs703184 132196688 Intron   G\C 0.09 12.2±5.8 (221) 11.9±6.2 (1150) 12.1±5.4 (13) 0.484 0.504 0.929 
rs7775386 132198842 Intron   T\C 0.49 11.9±6.4 (650) 11.9±6.3 (373) 12.0±5.9 (338) 0.840 0.819 0.862 
rs6916495 132201958 Intron   C\T 0.11 11.7±5.8 (261) 12.1±6.3 (1092) 13.7±6.9 (23) 0.591 0.909 0.194 
rs9493110 132203671 Intron   C\T 0.24 12.2±6.8 (505) 11.9±5.8 (782) 12.5±6.9 (78) 0.412 0.363 0.537 
rs858345 132205310 Intron   C\T 0.36 12.3±6.2 (591) 12.0±6.7 (562) 11.3±4.8 (179) 0.985 0.419 0.095 
rs4141767 132206700 Intron   A\G 0.41 11.7±5.9 (654) 12.2±6.9 (485) 12.3±5.2 (226) 0.326 0.809 0.411 
rs6926970 132208983 Intron   A\C 0.21 12.2±6.5 (429) 11.9±6.2 (868) 11.8±5.8 (80) 0.499 0.663 0.785 
rs1044498 132214061 Exon C\A 0.14 12.2±6.4 (302) 11.9±6.2 (1036) 10.5±4.3 (38) 0.961 0.663 0.147 
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           rs7749493 132216752 Intron   G\T 0.24 12.2±6.5 (476) 11.9±6.2 (804) 11.1±4.5 (98) 0.882 0.598 0.119 
rs17060836 132230641 Intron   T\C 0.23 11.9±6.2 (464) 11.9±6.4 (814) 12.2±5.6 (76) 0.878 0.976 0.687 
           rs7769712 132235088 Intron   A\C 0.31 11.9±5.9 (560) 12.1±6.5 (632) 12.1±5.7 (137) 0.612 0.720 0.959 
rs7768480 132245125 
Intron 
(boundary) G\A 0.46 11.9±6.3 (670) 12.2±6.4 (418) 11.9±6.0 (301) 0.422 0.539 0.861 
rs12202373 132251394 Intron   T\C 0.09 11.5±5.8 (215) 12.1±6.2 (1139) 13.6±8.6 (12) 0.318 0.482 0.356 
rs9493118 132253058 Intron   C\T 0.31 12.1±6.4 (538) 11.9±6.1 (622) 11.8±6.2 (138) 0.826 0.969 0.659 
rs1804025 132253227 Exon A\G 0.23 11.9±6.3 (459) 12.0±6.2 (842) 12.3±6.9 (83) 0.972 0.900 0.696 
rs7754561 132254387 3' UTR G\A 0.13 12.2±5.9 (292) 11.9±6.3 (1019) 11.9±4.8 (30) 0.591 0.644 0.981 
rs7769993 132262945 3' UTR A\G 0.42 12.0±6.5 (641) 12.0±6.1 (489) 11.8±6.1 (257) 0.842 0.729 0.695 
rs9373000 132263399 3' UTR A\G 0.36 12.0±6.5 (620) 12.0±6.1 (575) 11.8±5.9 (185) 0.919 0.783 0.683 
 
* 1= Major Allele; 2= Minor Allele in Controls. Test models refer to the minor allele.  Bold: P-values <0.05 
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Table 7.  Single SNP Association Results for Insulin Resistance Estimated by HOMA 
 
Marker Position Location 
Major†/ 
MAF 
Controls 
*1/2 1/1 2/2 Additive  Dominant  Recessive 
Minor 
alleles Mean±SD Mean ± SD  Mean ±SD  P-value P-value P-value 
rs7773292 132141454 
 
C\T 0.22 2.9±1.6 (430) 2.7±1.5 (814) 2.7±1.4 (79) 0.303 0.144 0.730 
rs6925433 132161059 Promoter A\G 0.19 2.9±1.5 (406) 2.7±1.6 (885) 2.7±1.4 (48) 0.275 0.153 0.704 
rs13211931 132165417 Promoter G\T 0.09 2.7±1.5 (207) 2.8±1.6 (1150) 2.9±1.0 (17) 0.681 0.538 0.607 
rs6935458 132168013 Promoter A\G 0.43 2.8±1.6 (639) 2.7±1.5 (468) 2.9±1.6 (268) 0.073 0.136 0.143 
rs6936129 132168133 Promoter G\C 0.09 2.8±1.6 (223) 2.7±1.5 (1104) 2.8±1.3 (16) 0.462 0.421 0.982 
rs6569759 132174809 Intron   G\A 0.24 2.8±1.7 (485) 2.7±1.5 (809) 2.8±1.4 (88) 0.402 0.292 0.994 
rs6939185 132180880 Intron   G\A 0.09 2.8±1.3 (228) 2.7±1.6 (1161) 2.3±0.9 (15) 0.769 0.963 0.318 
rs9398995 132181896 Intron   T\C 0.22 2.7±1.5 (443) 2.8±1.6 (849) 2.8±1.7 (75) 0.529 0.402 0.889 
rs943004 132182569 Intron   C\T 0.22 2.7±1.5 (483) 2.7±1.5 (832) 3.1±1.9 (62) 0.309 0.629 0.087 
rs1830971 132190046 Intron   A\G 0.26 2.7±1.5 (526) 2.8±1.6 (747) 2.7±1.5 (100) 0.303 0.274 0.697 
rs1409181 132190993 Intron   C\G 0.31 2.7±1.6 (568) 2.8±1.6 (662) 2.6±1.4 (141) 0.263 0.370 0.331 
rs2021966 132192132 Intron   A\G 0.30 2.7±1.5 (575) 2.8±1.6 (677) 2.7±1.5 (123) 0.380 0.354 0.710 
rs7771841 132192798 Intron   G\A 0.22 2.8±1.5 (457) 2.8±1.6 (846) 2.5±1.2 (68) 0.561 0.859 0.242 
rs9372999 132194845 Intron   C\A 0.26 2.8±1.6 (490) 2.7±1.5 (743) 2.9±1.9 (106) 0.340 0.618 0.179 
rs858338 132194900 Intron   G\T 0.12 2.9±1.5 (302) 2.7±1.6 (1070) 2.6±1.2 (19) 0.313 0.227 0.696 
rs858339 132195590 Intron   T\A 0.32 2.8±1.5 (601) 2.8±1.7 (654) 2.7±1.4 (147) 0.842 0.906 0.811 
rs703184 132196688 Intron   G\C 0.09 2.8±1.5 (221) 2.7±1.5 (1150) 2.8±1.3 (13) 0.410 0.388 0.911 
rs7775386 132198842 Intron   T\C 0.49 2.8±1.6 (650) 2.7±1.6 (373) 2.7±1.4 (338) 1.00 0.839 0.834 
rs6916495 132201958 Intron   C\T 0.11 2.7±1.5 (261) 2.8±1.6 (1092) 3.2±1.7 (23) 0.983 0.653 0.177 
rs9493110 132203671 Intron   C\T 0.24 2.8±1.7 (505) 2.7±1.5 (782) 2.8±1.5 (78) 0.534 0.456 0.975 
rs858345 132205310 Intron   C\T 0.36 2.8±1.6 (591) 2.8±1.6 (562) 2.5±1.2 (179) 0.350 0.937 0.043 
rs4141767 132206700 Intron   A\G 0.41 2.7±1.5 (654) 2.8±1.7 (485) 2.8±1.4 (226) 0.802 0.340 0.443 
rs6926970 132208983 Intron   A\C 0.21 2.8±1.6 (429) 2.7±1.5 (868) 2.7±1.5 (80) 0.513 0.425 0.969 
rs1044498 132214061 Exon C\A 0.14 2.8±1.5 (302) 2.7±1.5 (1036) 2.5±1.2 (38) 0.584 0.835 0.261 
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rs7749493 132216752 Intron   G\T 0.24 2.8±1.6 (476) 2.7±1.5 (804) 2.5±1.1 (98) 0.548 0.963 0.123 
rs17060836 132230641 Intron   T\C 0.23 2.7±1.5 (464) 2.8±1.6 (814) 2.8±1.5 (76) 0.729 0.495 0.584 
rs7769712 132235088 Intron   A\C 0.31 2.7±1.5 (560) 2.8±1.6 (632) 2.8±1.5 (137) 0.695 0.526 0.852 
rs7768480 132245125 
Intron 
(boundary) G\A 0.46 2.7±1.6 (670) 2.8±1.6 (418) 2.8±1.5 (301) 0.731 0.489 0.866 
rs12202373 132251394 Intron   T\C 0.09 2.6±1.5 (215) 2.8±1.5 (1139) 3.0±1.9 (12) 0.501 0.383 0.575 
rs9493118 132253058 Intron   C\T 0.31 2.8±1.6 (538) 2.7±1.5 (622) 2.7±1.5 (138) 0.894 0.896 0.616 
rs1804025 132253227 Exon A\G 0.23 2.7±1.6 (459) 2.7±1.5 (842) 2.8±1.7 (83) 0.814 0.903 0.728 
rs7754561 132254387 3' UTR G\A 0.13 2.8±1.5 (292) 2.7±1.5 (1019) 2.7±1.1 (30) 0.513 0.420 0.868 
rs7769993 132262945 3' UTR A\G 0.42 2.7±1.6 (641) 2.8±1.5 (489) 2.7±1.5 (257) 0.824 0.858 0.850 
rs9373000 132263399 3' UTR A\G 0.36 2.8±1.6 (620) 2.8±1.5 (575) 2.7±1.4 (185) 0.766 0.897 0.680 
 
* 1= Major Allele; 2= Minor Allele in Controls. Test models refer to the minor allele.  Bold: P-values <0.05 
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Table 8. Single-SNP Genotypic Tests of Association with T2D 
 
Locations Marker 
Major†/   
Minor 
alleles 
Dominant* 
P-value OR (95% CI) 
Additive          
P-value OR (95% CI) 
Recessive 
P-value OR (95% CI) 
 rs7773292 C\T 0.623 1.06 (0.83-1.35) 0.995 1.00 (0.82-1.22) 0.311 0.75 (0.43-1.31) 
Promoter rs6925433 A\G 0.179 1.18 (0.93-1.51) 0.206 1.14 (0.93-1.40) 0.734 1.11 (0.61-2.04) 
Promoter rs13211931 G\T 0.270 1.18 (0.88-1.60) - - - - 
Promoter rs6935458 A\G 0.139 0.84 (0.66-1.06) 0.310 0.92 (0.78-1.08) 0.945 0.99 (0.74-1.32) 
Promoter rs6936129 G\C 0.110 0.77 (0.55-1.06) - - - - 
Intron   rs6569759 G\A 0.622 0.94 (0.74-1.19) 0.906 1.01 (0.84-1.22) 0.209 1.32 (0.86-2.03) 
Intron   rs6939185 G\A 0.482 1.11 (0.83-1.49) - - - - 
Intron   rs9398995 T\C 0.627 0.94 (0.74-1.20) 0.596 0.95 (0.78-1.15) 0.725 0.91 (0.54-1.54) 
Intron   rs943004 C\T 0.182 0.85 (0.67-1.08) 0.251 0.89 (0.72-1.09) 0.940 0.98 (0.56-1.72) 
Intron   rs1830971 A\G 0.848 0.98 (0.78-1.23) 0.907 0.99 (0.82-1.19) 0.932 1.02 (0.66-1.59) 
Intron   rs1409181 C\G 0.534 0.93 (0.74-1.17) 0.335 0.92 (0.77-1.09) 0.276 0.80 (0.53-1.20) 
Intron   rs2021966 A\G 0.590 0.94 (0.74-1.18) 0.560 0.95 (0.79-1.14) 0.705 0.92 (0.61-1.40) 
Intron   rs7771841 G\A 0.440 0.91 (0.71-1.16) 0.302 0.90 (0.73-1.10) 0.285 0.72 (0.39-1.32) 
Intron   rs9372999 C\A 0.287 1.14 (0.90-1.44) 0.509 1.06 (0.88-1.28) 0.686 0.91 (0.58-1.43) 
Intron   rs858338 G\T 0.101 1.24 (0.96-1.62) - - - - 
Intron   rs858339 T\A 0.473 1.09 (0.86-1.37) 0.543 1.05 (0.89-1.25) 0.880 1.03 (0.71-1.49) 
Intron   rs703184 G\C 0.023 1.39 (1.05-1.85) - - - - 
Intron   rs7775386 T\C 0.924 1.01 (0.78-1.31) 0.473 0.94 (0.80-1.11) 0.193 0.83 (0.63-1.10) 
Intron   rs6916495 C\T 0.193 1.20 (0.91-1.58) - - - - 
Intron   rs9493110 C\T 0.527 1.08 (0.85-1.36) 0.553 1.06 (0.88-1.28) 0.843 1.05 (0.65-1.71) 
Intron   rs858345 C\T 0.633 0.94 (0.74-1.20) 0.531 0.95 (0.80-1.12) 0.568 0.90 (0.63-1.29) 
Intron   rs4141767 A\G 0.681 1.05 (0.83-1.34) 0.587 1.05 (0.89-1.24) 0.626 1.08 (0.80-1.46) 
Intron   rs6926970 A\C 0.052 0.78 (0.61-1.00) 0.058 0.82 (0.67-1.01) 0.400 0.79 (0.46-1.36) 
Exon rs1044498 C\A 0.079 0.78 (0.58-1.03) - - - - 
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Intron   rs7749493 G\T 0.037 0.78 (0.61-0.99) 0.020 0.79 (0.65-0.96) 0.095 0.64 (0.38-1.08) 
Intron   rs17060836 T\C 0.021 1.32 (1.04-1.67) 0.092 1.18 (0.97-1.43) 0.562 0.85 (0.50-1.46) 
Intron   rs7769712 A\C 0.567 1.07 (0.85-1.36) 0.822 1.02 (0.85-1.22) 0.650 0.91 (0.61-1.36) 
Intron 
(boundary) rs7768480 G\A 0.762 0.96 (0.75-1.23) 0.559 0.95 (0.81-1.12) 0.498 0.91 (0.68-1.20) 
Intron   rs12202373 T\C 0.259 0.83 (0.60-1.15) - - - - 
Intron   rs9493118 C\T 0.220 1.16 (0.91-1.48) 0.269 1.10 (0.93-1.32) 0.681 1.08 (0.74-1.58) 
Exon rs1804025 A\G 0.231 1.15 (0.91-1.46) 0.368 1.09 (0.90-1.32) 0.867 0.96 (0.59-1.57) 
3’UTR rs7754561 G\A 0.020 0.70 (0.52-0.95) - - - - 
3’UTR rs7769993 A\G 0.026 1.33 (1.03-1.71) 0.249 1.10 (0.93-1.30) 0.533 0.91 (0.67-1.23) 
3’UTR rs9373000 A\G 0.008 1.38 (1.08-1.76) 0.019 1.22 (1.03-1.44) 0.339 1.17 (0.85-1.62) 
 
*Only the dominant model was considered where the minor allele homozygote count for either cases or controls was <10.  Test 
models refer to the minor allele.  †Major allele is defined as most common allele in controls.  ‡Dominant model.  Bold: P-values 
<0.05. 
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Table 9.  Genotype Frequencies in Afro-Caribbean Case and Control Groups 
 
Marker Marker Position* 
Marker 
Location 
Major†/ 
Minor 
T2D Cases Controls 
Frequency (n) Frequency (n) 
      alleles 1/1 1/2 2/2 1/1 1/2 2/2 
rs7773292 132141454  C\T 0.598 (207) 0.355 (123) 0.046 (16) 0.615 (814) 0.325 (430) 0.059 (79) 
rs6925433 132161059 Promoter A\G 0.620 (219) 0.339 (120) 0.039 (14) 0.661 (885) 0.303 (406) 0.036 (48) 
rs13211931 132165417 Promoter G\T 0.813 (295) 0.179 (65) 0.008 (3) 0.837 (1150) 0.151 (207) 0.012 (17) 
rs6935458 132168013 Promoter A\G 0.383 (140) 0.426 (156) 0.191 (70) 0.340 (468) 0.465 (639) 0.195 (268) 
rs6936129 132168133 Promoter G\C 0.859 (307) 0.132 (47) 0.008 (3) 0.822 (1104) 0.166 (223) 0.012 (16) 
rs6569759 132174809 Intron   G\A 0.598 (216) 0.319 (115) 0.083 (30) 0.585 (809) 0.351 (485) 0.064 (88) 
rs6939185 132180880 Intron   G\A 0.809 (298) 0.177 (65) 0.014 (5) 0.827 (1161) 0.162 (228) 0.011 (15) 
rs9398995 132181896 Intron   T\C 0.635 (228) 0.315 (113) 0.050 (18) 0.621 (849) 0.324 (443) 0.055 (75) 
rs943004 132182569 Intron   C\T 0.644 (230) 0.310 (111) 0.045 (16) 0.604 (832) 0.351 (483) 0.045 (62) 
rs1830971 132190046 Intron   A\G 0.549 (200) 0.376 (137) 0.074 (27) 0.544 (747) 0.383 (526) 0.073 (100) 
rs1409181 132190993 Intron   C\G 0.501 (180) 0.415 (149) 0.084 (30) 0.483 (662) 0.414 (568) 0.103 (141) 
rs2021966 132192132 Intron   A\G 0.509 (184) 0.407 (147) 0.083 (30) 0.492 (677) 0.418 (575) 0.089 (123) 
rs7771841 132192798 Intron   G\A 0.641 (230) 0.323 (116) 0.036 (13) 0.617 (846) 0.333 (457) 0.049 (68) 
rs9372999 132194845 Intron   C\A 0.522 (178) 0.405 (138) 0.073 (25) 0.554 (743) 0.366 (490) 0.079 (106) 
rs858338 132194900 Intron   G\T 0.727(264) 0.259 (94) 0.014 (5) 0.769 (1070) 0.217 (302) 0.014 (19) 
rs858339 132195590 Intron   T\A 0.446 (166) 0.446 (166) 0.108 (40) 0.466 (654) 0.429 (601) 0.105 (147) 
rs703184 132196688 Intron   G\C 0.779 (285) 0.216 (79) 0.005 (2) 0.831 (1150) 0.159 (221) 0.009 (13) 
rs7775386 132198842 Intron   T\C 0.272 (98) 0.514 (185) 0.214 (77) 0.274 (373) 0.478 (650) 0.248 (338) 
rs6916495 132201958 Intron   C\T 0.762 (279) 0.227 (83) 0.011 (4) 0.794 (1092) 0.189 (261) 0.017 (23) 
rs9493110 132203671 Intron   C\T 0.554 (201) 0.386 (140) 0.061 (22) 0.573 (782) 0.369 (505) 0.057 (78) 
rs858345 132205310 Intron   C\T 0.437 (153) 0.443 (155) 0.120 (42) 0.422 (562) 0.444 (591) 0.134 (179) 
rs4141767 132206700 Intron   A\G 0.344 (125) 0.482 (175) 0.174 (63) 0.355 (485) 0.479 (654) 0.166 (226) 
rs6926970 132208983 Intron   A\C 0.684 (249) 0.269 (98) 0.047 (17) 0.630 (868) 0.312 (429) 0.058 (80) 
rs1044498 132214061 Exon C\A 0.797 (286) 0.178 (64) 0.025 (9) 0.753 (1036) 0.219 (302) 0.028 (38) 
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rs7749493 132216752 Intron   G\T 0.643 (234) 0.310 (113) 0.047 (17) 0.583 (804) 0.345 (476) 0.071(98) 
rs17060836 132230641 Intron   T\C 0.531 (187) 0.420 (148) 0.048 (17) 0.601 (814) 0.343 (464) 0.056 (76) 
rs7769712 132235088 Intron   A\C 0.459 (160) 0.448 (156) 0.091 (32) 0.476 (632) 0.421 (560) 0.103 (137) 
rs7768480 132245125 Intron (boundary) G\A 0.309 (114) 0.492 (181) 0.198 (73) 0.301 (418) 0.482 (670) 0.217 (301) 
rs12202373 132251394 Intron   T\C 0.858 (309) 0.122 (44) 0.019 (7) 0.833 (1139) 0.157 (215) 0.009 (12) 
rs9493118 132253058 Intron   C\T 0.442 (150) 0.442 (150) 0.115 (39) 0.479 (622) 0.414 (538) 0.106 (138) 
rs1804025 132253227 Exon A\G 0.575 (207) 0.367 (132) 0.058 (21) 0.608 (842) 0.332 (459) 0.059 (83) 
rs7754561 132254387 3' UTR G\A 0.819 (280) 0.175 (60) 0.006 (2) 0.759 (1019) 0.218 (292) 0.022 (30) 
rs7769993 132262945 3' UTR A\G 0.288 (104) 0.540 (195) 0.172 (62) 0.353 (489) 0.462 (641) 0.185 (257) 
rs9373000 132263399 3' UTR A\G 0.339 (123) 0.507 (184) 0.154 (56) 0.417 (575) 0.4491 (620) 0.134 (185) 
 
*NCBI Build 36.1 (March 2006).  †Major allele is defined as most common allele in control. 
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